Danoprevir Sodium/Ritonavir

达诺瑞韦钠/利托那韦

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDanoprevir Sodium/Ritonavir
Drug Alias NameRitonavir/Danoprevir Sodium利托那韦/丹诺瑞韦钠Danoprevir and ritonavirDanoprevir/ritonavir
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanThailandSouth Korea
CombinationsYes Danoprevir SodiumRitonavir
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksN/A